Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Barbara Ann Karmanos Cancer Institute
Modality
protein_peptide
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00482846CT.gov Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma | — | Completed | — | — | — |
NCT00101582CT.gov Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Mucositis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Palifermin (this asset) | Barbara Ann Karmanos Cancer Institute | P3 | BB · 64 |
| Fentanyl Sublingual Spray | INSYS Therapeutics Inc | P3 | BB |
| Calcium Phosphate | Children's Oncology Group | P3 | BB |
| Everolimus | Emory University | P2 | CCC |
| Folic Acid | Niels Fristrup | P2 | CCC |
| tk-112690 | Tosk, Inc. | P2 | CCC |
| Methotrexate | University College, London | P1/2 | CCC |
| Pteroylmonoglutamic Acid Hydrolase G2 | University College, London | P1/2 | CCC |
| Melphalan | Sherif S. Farag | P1 | CC |
+1 more in the Mucositis cohort
Other indications for Palifermin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Hodgkin Lymphoma | — | P4 | B · 63 |
| Plasma Cell Myeloma | — | P4 | B · 61 |
| Lymphoma | — | P3 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Palifermin in Mucositis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/palifermin-mucositis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →